Hanyu Pharmaceutical announced that the company recently received the “Notice of Acceptance” for the HY3003 tablet clinical trial application approved and issued by the State Drug Administration, with a total of 4 acceptance numbers. HY3003 tablets are GLP-1R/GIPR/GCGR triple agonist oral formulations arranged by the company. They are intended for use in weight loss, type 2 diabetes, metabolism-related steatohepatitis, etc. The specifications are 10mg, 20mg, 40mg, and 60mg, and are registered as Class 1 chemicals. The acceptance of this clinical trial marks that the variety has officially entered the clinical development stage. Subsequent phase I, phase II, and phase III clinical trials need to be completed and reviewed before it can be marketed.

Zhitongcaijing · 1d ago
Hanyu Pharmaceutical announced that the company recently received the “Notice of Acceptance” for the HY3003 tablet clinical trial application approved and issued by the State Drug Administration, with a total of 4 acceptance numbers. HY3003 tablets are GLP-1R/GIPR/GCGR triple agonist oral formulations arranged by the company. They are intended for use in weight loss, type 2 diabetes, metabolism-related steatohepatitis, etc. The specifications are 10mg, 20mg, 40mg, and 60mg, and are registered as Class 1 chemicals. The acceptance of this clinical trial marks that the variety has officially entered the clinical development stage. Subsequent phase I, phase II, and phase III clinical trials need to be completed and reviewed before it can be marketed.